Symbol="KRBP"
AssetType="Common Stock"
Name="Kiromic BiopharmaÂ Inc"
Description="Kiromic BioPharma, Inc., a gene editing and target discovery company, focuses on the development of immuno-oncology therapies for the treatment of blood cancers and solid tumors. The company is headquartered in Houston, Texas."
CIK="1792581"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="7707 FANNIN ST., SUITE 140, HOUSTON, TX, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="2058500"
EBITDA="-22190000"
PERatio="None"
PEGRatio="None"
BookValue="-5.35"
DividendPerShare="0"
DividendYield="0"
EPS="-38.54"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.919"
ReturnOnEquityTTM="-11.3"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-38.54"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="None"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="15.11"
EVToRevenue="-"
EVToEBITDA="-0.163"
Beta="0.155"
num_52WeekHigh="15.3"
num_52WeekLow="1.75"
num_50DayMovingAverage="2.623"
num_200DayMovingAverage="4.601"
SharesOutstanding="1176300"
DividendDate="None"
ExDividendDate="None"
symbol="KRBP"
open="1.88"
high="1.88"
low="1.75"
price="1.75"
volume="9732.00"
latest_trading_day="2023-08-25"
previous_close="1.90"
change="-0.15"
change_percent="-7.8947%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="56"
trend_strength="Strong Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="232121"
Change_recent_avg="-0.02"
Delta_recent_avg="0.51"
Variance_recent_avg="0.26"
Change_ratio_recent_avg="-1.0"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="1089"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0122.jpeg"
image_negative_thumbnail_id_2="138"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0038.jpeg"
image_neutral_thumbnail_id_1="588"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0011.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="666"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0042.jpeg"
image_positive_thumbnail_id_2="991"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0153.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
